Form Type:  SC 13G/A
Filing Date:  2/12/2020 
CIK:  0001439222 
Address:  88 SIDNEY STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  617-649-8600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
1.09 (2.20%)  
Trade Time: 
Jun 05  
Market Cap: 
Trade AGIO now with 

© 2020  
Description of Business
Item 1. Business We are a biopharmaceutical company committed to the fundamental transformation of patients' lives through scientific leadership in the field of cellular metabolism, with the goal of making transformative, first- or best-in-class medicines. Our therapeutic areas of focus are cancer and rare genetic diseases, or RGDs, which are diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Most RGDs are often associated with severe or life-threatening features. The incidence of a single RGD can vary widely but is generally very infrequent, usually equal to or less than one per 100,000 births. In both areas of cancer and RGDs, we are seeking to unlock the biology of cellular metabolism as a platform to create transformative therapies. Our first commercial cancer product is IDHIFA®.
Register and access this filing in: